PURPOSE: To investigate the association of postdiagnosis body mass index (BMI) and weight change with prostate cancer-specific mortality (PCSM), cardiovascular disease-related mortality (CVDM), and all-cause mortality among survivors of nonmetastatic prostate cancer. METHODS: Men in the Cancer Prevention Study II Nutrition Cohort diagnosed with nonmetastatic prostate cancer between 1992 and 2013 were followed for mortality through December 2016. Current weight was self-reported on follow-up questionnaires approximately every 2 years. Postdiagnosis BMI was obtained from the first survey completed 1 to < 6 years after diagnosis. Weight change was the difference in weight between the first and second postdiagnosis surveys. Deaths occurring within 4 years of the follow-up were excluded to reduce bias from reverse causation. Analyses of BMI and weight change included 8,330 and 6,942 participants, respectively. RESULTS: Postdiagnosis BMI analyses included 3,855 deaths from all causes (PCSM, n = 500; CVDM, n = 1,155). Using Cox proportional hazards models, hazard ratios (HRs) associated with postdiagnosis obesity (BMI ≥ 30 kg/m2) compared with healthy weight (BMI 18.5 to < 25.0 kg/m2) were 1.28 for PCSM (95% CI, 0.96 to 1.67), 1.24 for CVDM (95% CI, 1.03 to 1.49), and 1.23 for all-cause mortality (95% CI, 1.11 to 1.35). Weight gain analyses included 2,973 deaths (PCSM, n = 375; CVDM, n = 881). Postdiagnosis weight gain (> 5% of body weight), compared with stable weight (± < 3%), was associated with a higher risk of PCSM (HR, 1.65; 95% CI, 1.21 to 2.25) and all-cause mortality (HR, 1.27; 95% CI, 1.12 to 1.45) but not CVDM. CONCLUSION: Results suggest that among survivors of nonmetastatic prostate cancer with largely localized disease, postdiagnosis obesity is associated with higher CVDM and all-cause mortality, and possibly higher PCSM, and that postdiagnosis weight gain may be associated with a higher mortality as a result of all causes and prostate cancer.
PURPOSE: To investigate the association of postdiagnosis body mass index (BMI) and weight change with prostate cancer-specific mortality (PCSM), cardiovascular disease-related mortality (CVDM), and all-cause mortality among survivors of nonmetastatic prostate cancer. METHODS:Men in the Cancer Prevention Study II Nutrition Cohort diagnosed with nonmetastatic prostate cancer between 1992 and 2013 were followed for mortality through December 2016. Current weight was self-reported on follow-up questionnaires approximately every 2 years. Postdiagnosis BMI was obtained from the first survey completed 1 to < 6 years after diagnosis. Weight change was the difference in weight between the first and second postdiagnosis surveys. Deaths occurring within 4 years of the follow-up were excluded to reduce bias from reverse causation. Analyses of BMI and weight change included 8,330 and 6,942 participants, respectively. RESULTS: Postdiagnosis BMI analyses included 3,855 deaths from all causes (PCSM, n = 500; CVDM, n = 1,155). Using Cox proportional hazards models, hazard ratios (HRs) associated with postdiagnosis obesity (BMI ≥ 30 kg/m2) compared with healthy weight (BMI 18.5 to < 25.0 kg/m2) were 1.28 for PCSM (95% CI, 0.96 to 1.67), 1.24 for CVDM (95% CI, 1.03 to 1.49), and 1.23 for all-cause mortality (95% CI, 1.11 to 1.35). Weight gain analyses included 2,973 deaths (PCSM, n = 375; CVDM, n = 881). Postdiagnosis weight gain (> 5% of body weight), compared with stable weight (± < 3%), was associated with a higher risk of PCSM (HR, 1.65; 95% CI, 1.21 to 2.25) and all-cause mortality (HR, 1.27; 95% CI, 1.12 to 1.45) but not CVDM. CONCLUSION: Results suggest that among survivors of nonmetastatic prostate cancer with largely localized disease, postdiagnosis obesity is associated with higher CVDM and all-cause mortality, and possibly higher PCSM, and that postdiagnosis weight gain may be associated with a higher mortality as a result of all causes and prostate cancer.
Authors: I Baik; A Ascherio; E B Rimm; E Giovannucci; D Spiegelman; M J Stampfer; W C Willett Journal: Am J Epidemiol Date: 2000-08-01 Impact factor: 4.897
Authors: Cheryl L Rock; Colleen Doyle; Wendy Demark-Wahnefried; Jeffrey Meyerhardt; Kerry S Courneya; Anna L Schwartz; Elisa V Bandera; Kathryn K Hamilton; Barbara Grant; Marji McCullough; Tim Byers; Ted Gansler Journal: CA Cancer J Clin Date: 2012-04-26 Impact factor: 508.702
Authors: Crystal S Langlais; Janet E Cowan; John Neuhaus; Stacey A Kenfield; Erin L Van Blarigan; Jeanette M Broering; Matthew R Cooperberg; Peter Carroll; June M Chan Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-08-28 Impact factor: 4.254
Authors: Howard S Kim; Daniel M Moreira; Matthew R Smith; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2010-09-22 Impact factor: 5.588
Authors: Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun Journal: Cancer Date: 2002-05-01 Impact factor: 6.860
Authors: Stephanie E Bonn; Fredrik Wiklund; Arvid Sjölander; Robert Szulkin; Pär Stattin; Erik Holmberg; Henrik Grönberg; Katarina Bälter Journal: Cancer Causes Control Date: 2014-05-09 Impact factor: 2.506
Authors: Ted A Skolarus; Andrew M D Wolf; Nicole L Erb; Durado D Brooks; Brian M Rivers; Willie Underwood; Andrew L Salner; Michael J Zelefsky; Jeanny B Aragon-Ching; Susan F Slovin; Daniela A Wittmann; Michael A Hoyt; Victoria J Sinibaldi; Gerald Chodak; Mandi L Pratt-Chapman; Rebecca L Cowens-Alvarado Journal: CA Cancer J Clin Date: 2014-06-10 Impact factor: 508.702
Authors: Daniel A Galvão; Dennis R Taaffe; Dickon Hayne; Pedro Lopez; P Lyons-Wall; Colin I Tang; Suzanne K Chambers; Amanda Devine; Nigel Spry; Emily Jeffery; Christine Kudiarasu; David Joseph; Robert U Newton Journal: BMJ Open Date: 2022-06-06 Impact factor: 3.006
Authors: Qianyu Yuan; Mulong Du; Elizabeth Loehrer; Bruce E Johnson; Justin F Gainor; Michael Lanuti; Yi Li; David C Christiani Journal: Cancer Epidemiol Biomarkers Prev Date: 2021-11-02 Impact factor: 4.090
Authors: Oliver Schumacher; Daniel A Galvão; Dennis R Taaffe; Nigel Spry; Dickon Hayne; Colin Tang; Raphael Chee; Robert U Newton Journal: JCO Oncol Pract Date: 2022-05-18
Authors: Crystal S Langlais; Rebecca E Graff; Erin L Van Blarigan; Nynikka R Palmer; Samuel L Washington; June M Chan; Stacey A Kenfield Journal: Curr Oncol Rep Date: 2021-03-10 Impact factor: 5.075
Authors: Rebekah L Wilson; Dennis R Taaffe; Robert U Newton; Nicolas H Hart; Philippa Lyons-Wall; Daniel A Galvão Journal: Nutrients Date: 2021-05-14 Impact factor: 5.717